Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer

INTRODUCTION: Exemestane was approved in 2005 for adjuvant treatment of breast cancer. In this study, we aimed to assess whether it is cost-effective in comparison to available alternatives. MATERIAL AND METHODS: To evaluate the efficacy of exemestane, a systematic review was conducted by searching...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemi-Meshkini, Amir, Keshavarz, Khosro, Gharibnaseri, Zahra, Kheirandish, Mehrnaz, Kebriaeezadeh, Abbas, Nikfar, Shekoufeh, Abdollahi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2013
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701982/
https://www.ncbi.nlm.nih.gov/pubmed/23847669
http://dx.doi.org/10.5114/aoms.2013.35347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701982/
https://www.ncbi.nlm.nih.gov/pubmed/23847669
http://dx.doi.org/10.5114/aoms.2013.35347

Ejemplares similares